IL2 and splenic marginal zone lymphoma: All the 3 evaluable patients with advanced, progressive B-NHL (2 FL, 1 splenic marginal zone lymphoma (SMZL)) who received conditioning chemotherapy followed by an infusion of anti-CD19 28ζ CAR-T cells and a course of IL-2 obtained PR.